J.C. Hassel

407 total citations
16 papers, 278 citations indexed

About

J.C. Hassel is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, J.C. Hassel has authored 16 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Immunology. Recurrent topics in J.C. Hassel's work include Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (7 papers) and Melanoma and MAPK Pathways (7 papers). J.C. Hassel is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (7 papers) and Melanoma and MAPK Pathways (7 papers). J.C. Hassel collaborates with scholars based in Germany, United States and Australia. J.C. Hassel's co-authors include Caroline Robert, Georgina V. Long, Paolo A. Ascierto, Piotr Rutkowski, Kerry J. Savage, Cheryl D. Coon, Ian M. Waxman, Amy P. Abernethy, Victoria Atkinson and Fiona Taylor and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J.C. Hassel

13 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.C. Hassel Germany 8 243 104 86 31 25 16 278
Nikolaus B. Wagner Germany 11 223 0.9× 138 1.3× 139 1.6× 48 1.5× 5 0.2× 22 340
Clara Allayous France 8 169 0.7× 76 0.7× 41 0.5× 41 1.3× 23 0.9× 31 208
J A P Spijkers-Hagelstein Netherlands 7 55 0.2× 150 1.4× 54 0.6× 25 0.8× 28 1.1× 9 293
Luca Paruzzo Italy 6 99 0.4× 71 0.7× 47 0.5× 33 1.1× 18 0.7× 12 192
Eva Zebedin-Brandl Austria 8 134 0.6× 89 0.9× 145 1.7× 24 0.8× 22 0.9× 18 267
J. Casal Spain 10 195 0.8× 40 0.4× 44 0.5× 170 5.5× 9 0.4× 29 327
Tanja Badovinac Črnjević Switzerland 9 238 1.0× 50 0.5× 39 0.5× 106 3.4× 16 0.6× 16 326
Habte Yimer United States 9 156 0.6× 106 1.0× 36 0.4× 12 0.4× 75 3.0× 48 270
Amanda Ralabate United States 5 376 1.5× 115 1.1× 138 1.6× 192 6.2× 66 2.6× 5 426
Roha Afzal United States 2 204 0.8× 193 1.9× 99 1.2× 68 2.2× 12 0.5× 2 327

Countries citing papers authored by J.C. Hassel

Since Specialization
Citations

This map shows the geographic impact of J.C. Hassel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.C. Hassel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.C. Hassel more than expected).

Fields of papers citing papers by J.C. Hassel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.C. Hassel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.C. Hassel. The network helps show where J.C. Hassel may publish in the future.

Co-authorship network of co-authors of J.C. Hassel

This figure shows the co-authorship network connecting the top 25 collaborators of J.C. Hassel. A scholar is included among the top collaborators of J.C. Hassel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.C. Hassel. J.C. Hassel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Sullivan, Ryan J., J.C. Hassel, Teresa Amaral, et al.. (2025). 954P A randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001). Annals of Oncology. 36. S585–S585.
2.
Hassel, J.C., Michael Erdmann, Katharina C. Kähler, et al.. (2024). 1107P Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab. Annals of Oncology. 35. S733–S734. 1 indexed citations
3.
Dimitriou, Florentia, J.C. Hassel, Marlana Orloff, et al.. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology. 33. S929–S929. 3 indexed citations
4.
5.
6.
Jordan, Berit, Karolina Benesova, J.C. Hassel, Wolfgang Wick, & Karin Jordan. (2021). How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open. 6(6). 100317–100317. 21 indexed citations
7.
Benesova, Karolina, L. Diekmann, H.-M. Lorenz, et al.. (2020). 1809O TRheuMa registry provides real world data on rheumatic immune-related adverse events. Annals of Oncology. 31. S1046–S1046.
8.
D’Angelo, Sandra P., Jeffery S. Russell, J.C. Hassel, et al.. (2017). Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC). Annals of Oncology. 28. v435–v436. 2 indexed citations
9.
Long, Georgina V., James Larkin, Paolo A. Ascierto, et al.. (2016). PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. Annals of Oncology. 27. vi381–vi381. 18 indexed citations
10.
Long, Georgina V., Victoria Atkinson, Paolo A. Ascierto, et al.. (2016). Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Annals of Oncology. 27(10). 1940–1946. 89 indexed citations
11.
12.
Larkin, James, Vanna Chiarion‐Sileni, R. Gonzalez, et al.. (2015). 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). European Journal of Cancer. 51. S664–S665. 27 indexed citations
13.
14.
Hassel, J.C., Antje Sucker, Lutz Edler, et al.. (2010). MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. British Journal of Cancer. 103(6). 820–826. 38 indexed citations
15.
Hauschild, Axel, Ralf Gutzmer, Selma Ugurel, et al.. (2010). Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.. Journal of Clinical Oncology. 28(15_suppl). 8526–8526. 2 indexed citations
16.
Hauschild, Axel, Ralf Gutzmer, Selma Ugurel, et al.. (2010). FC10 Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Melanoma Research. 20. e33–e33. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nikolaus B. Wagner Breakdown of academic impact, for papers by Clara Allayous Breakdown of academic impact, for papers by J A P Spijkers-Hagelstein Breakdown of academic impact, for papers by Luca Paruzzo Breakdown of academic impact, for papers by Eva Zebedin-Brandl Breakdown of academic impact, for papers by J. Casal Breakdown of academic impact, for papers by Tanja Badovinac Črnjević Breakdown of academic impact, for papers by Habte Yimer Breakdown of academic impact, for papers by Amanda Ralabate Breakdown of academic impact, for papers by Roha Afzal
Rankless by CCL
2026